Login
Israel-Hamas Conflict
Donald Trump
Military
Boxing
World Cup
Social Media
Baseball
Soccer
Juneteenth
Airstrike
Parade
Rallies
Protestors
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Inebilizumab Efficacy and Safety Consistent Across Demographic Subgroups of IgG4-RD

Summary by hcplive.com
Inebilizumab was approved by the FDA under the name Uplizna as the first and only treatment for adult patients with IgG4-RD in April 2025
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
hcplive.comhcplive.com

Inebilizumab Efficacy and Safety Consistent Across Demographic Subgroups of IgG4-RD

Inebilizumab was approved by the FDA under the name Uplizna as the first and only treatment for adult patients with IgG4-RD in April 2025

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

hcplive.com broke the news in on Friday, June 13, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

FDA

FDA

United States

United States

News
For You
SearchBlindspotLocal